XML 13 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Series 1 Preferred
Preferred stock, beginning balance (in shares) at Dec. 31, 2020             452,000
Preferred stock, beginning balance at Dec. 31, 2020             $ 18,036
Preferred stock, ending balance (in shares) at Mar. 31, 2021             452,000
Preferred stock, ending balance at Mar. 31, 2021             $ 18,036
Balance, beginning of period (in shares) at Dec. 31, 2020   8,385,650 67,746        
Balance, beginning of period at Dec. 31, 2020 $ (2,497) $ 84 $ (5,056) $ 543,561 $ (540,747) $ (339)  
Increase (Decrease) in Stockholders' Equity              
Share-based compensation 903     903      
Exercise of restricted stock unit awards (in shares)   369          
Comprehensive loss (11,267)       (11,267) 0  
Balance, end of period (in shares) at Mar. 31, 2021   8,386,019 67,746        
Balance, end of period at Mar. 31, 2021 (12,861) $ 84 $ (5,056) 544,464 (552,014) (339)  
Preferred stock, beginning balance (in shares) at Dec. 31, 2021             452,000
Preferred stock, beginning balance at Dec. 31, 2021 18,036           $ 18,036
Preferred stock, ending balance (in shares) at Mar. 31, 2022             452,000
Preferred stock, ending balance at Mar. 31, 2022 18,036           $ 18,036
Balance, beginning of period (in shares) at Dec. 31, 2021   8,497,025 67,746        
Balance, beginning of period at Dec. 31, 2021 24,395 $ 85 $ (5,056) 580,156 (550,452) (338)  
Increase (Decrease) in Stockholders' Equity              
Share-based compensation 599     599      
Issuance of common stock upon vesting of restricted stock units (in shares)   122,928          
Issuance of common stock upon vesting of restricted stock units 0 $ 1   (1)      
Issuance of common stock upon exercise of pre-funded warrants (in shares)   56,950          
Issuance of common stock upon exercise of pre-funded warrants 0 $ 1   (1)      
Comprehensive loss (7,565)       (7,562) (3)  
Balance, end of period (in shares) at Mar. 31, 2022   8,676,903 67,746        
Balance, end of period at Mar. 31, 2022 $ 17,429 $ 87 $ (5,056) $ 580,753 $ (558,014) $ (341)